Clinical data show remibrutinib treatment leads to significant reductions in urticaria activity scores compared with placebo within the first week.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results